Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HL151 vs Talion in Healthy Males
NCT02686294Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Feb 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bepotastine in perennial allergic rhinitis (PAR) (2 arms), sponsored by Hanlim Pharm. Primary endpoints: Area under the plasma concentration-time curve during a dosing interval at steady state and Maximum plasma concentration at steady state. Started Feb 2016; status: completed.
02
Drugs
bepotastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT02686294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686294.